Genzyme's patient focus led us to pioneer therapeutic treatments for rare genetic diseases known as lysosomal storage disorders (LSDs). We now have three marketed LSD products, and a fourth has entered the regulatory approval process. Our continued success is based on our ability to meet medical needs and our global commitment to patient care.

Fabrazyme, our enzyme replacement therapy for Fabry disease, grew rapidly in 2004 — revenue more than doubled, and now the majority of treated Fabry patients in Europe use our product. In 2004, Fabrazyme was launched in more than 23 markets, including Japan, and we believe that it will be a growth driver for Genzyme in 2005. A phase 4 post-marketing study was successfully completed in 2004. Fabry patients demonstrated a high level of commitment by volunteering for this placebo-controlled study of their potentially fatal disease despite the availability of commercial treatment. In early 2005, we filed a supplemental application with the U.S. Food and Drug Administration (FDA) to obtain changes in the product label that incorporate the findings of this study, and we are taking similar steps in Europe and other regions.

Aldurazyme, which we developed jointly with BioMarin Pharmaceutical Inc. to treat MPS I, is now available in more than 30 markets. MPS I attacks young children, and we are engaged in educating pediatricians to accelerate referrals to geneticists for diagnosis and treatment. To validate our belief that early treatment can improve outcomes, we are conducting a study of MPS I patients under age 5 that should be completed in 2005.

Cerezyme, the world's standard of care for Gaucher disease, continued to grow steadily. We focused on product and service enhancements and on providing greater access, both commercial and humanitarian, to patients throughout the world.

We are pursuing a global strategy for Myozyme, our enzyme replacement therapy for Pompe disease, which we are preparing to launch in early 2006.